Media kit | Tomorrow.bio

About Tomorrow.bio

Who we are

We are the first human cryopreservation company safely made in Europe, now also covering the US. Founded in 2020 by Dr Emil Kendziorra and Fernando Azevedo Pinheiro, our Berlin-based team of medical professionals and engineers is dedicated to providing high-quality cryopreservation services.

What human cryopreservation is, and why it is not freezing

Human cryopreservation, also known as biostasis or cryonics, is an advanced medical procedure that puts a human into complete biological pause after their legal death. The purpose is to keep people preserved until medical technology has advanced enough to treat their cause of death and revive them. It gives patients the chance to benefit from future technology.

Normal freezing causes ice crystals to form inside cells, damaging their structure. We do not freeze people, even though we keep them at very low temperatures. Instead we use vitrification, the transformation into a glass-like state, achieved by first replacing the blood with a medical-grade cryoprotectant solution.

How cryopreservation works

Sign-up

Patients wishing to be cryopreserved sign up for a membership with Tomorrow.bio. We help them get the necessary paperwork in order, ensure there is insurance or funds in place to pay for the procedure, and stay ready to cryopreserve them whenever death occurs.

Dispatch

Most deaths can be predicted by medical conditions and circumstances. When there are signs that a patient might be dying, we dispatch one of our ambulances with a biostasis response team. They usually arrive before death occurs, so stabilisation can start as soon as the patient is legally pronounced dead.

Stabilisation

We cool the patient down as quickly as possible using ice and water. Then we initiate cardiopulmonary support (CPS) and infuse neuroprotective and anti-clotting medication. This slows down degradation and prepares the patient for cryoprotection.

Cryoprotection

Our ambulances are fully equipped to perform field cryopreservation. We slowly replace the patient’s blood with cryoprotectant and cool them down further. The cryoprotectant protects the body during the cooldown.

Transport

We transport the patient to our storage facility in Switzerland, by ambulance or plane depending on the distance.

Cooldown

At the facility, patients are placed in a cooldown chamber and cooled as quickly as possible to −120 °C, where they undergo vitrification, a glass-like transition of the body. We then slow the cooldown to about 1 °C per hour to avoid thermal stress, until the patient reaches −196 °C.

Storage

Patients are placed in a pod inside a cryogenic dewar filled with liquid nitrogen. Here they are stored indefinitely, with no electricity required. The liquid nitrogen is regularly refilled by the on-site team or an automated system.

European Biostasis Foundation

Tomorrow.bio stores its patients at the European Biostasis Foundation’s underground facility in Switzerland, designed for long-term stability and security. Switzerland was chosen for its security, socio-economic stability, strict oversight of non-profits and low risk of natural disasters.

EBF is a non-profit organisation that works together with Tomorrow.bio to provide a high-quality and secure cryopreservation service.